News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
Quanterix Corporation, a company that digitizes biomarker analysis, has announced an investment in its Simoa Accelerator Lab services. As part of the investment, the company has appointed Daniel Sikkema, Ph.D., as vice president of Accelerator Services.
Launched in early 2014, the Simoa Accelerator Lab is a dedicated environment for biomarker research, custom assay development, and clinical sample testing.
According to the company, Sikkema will work to expand the reach of Quanterix’ Accelerator Lab Services in neurology, oncology, immuno-oncology, infectious disease, inflammatory diseases, and other therapeutic areas.
“My goal is to help further Quanterix’ mission to transform precision healthcare, by putting more of a focus on health, rather than disease. By working to expand the Lab’s services in neurology, oncology, cardiology, immuno-oncology, infectious and rare diseases, inflammatory diseases and other therapeutic areas, we’ll be poised to accelerate research in these key areas to change the way diseases are diagnosed and treated and advance drug development,” Sikkema told Outsourcing-Pharma.com.
“Furthermore, I believe that every individual has the power to change medicine. The privilege to work with the world’s best technology and scientists should not lie solely within the hands of big players,” he added.
“I want to bring the capabilities of Quanterix’ Simoa technology and Accelerator Lab services to an extended number of researchers and academics, so that we can all work together to inspire new medical breakthroughs.”
Sikkema has worked at Frontage Lab, Bristol-Myers Squibb, Wyeth, Merck, Sanofi Pasteur, and GlaxoSmithKline.
He has also worked with the World Health Organization (WHO), National Institute for Biological Standards and Controls (NIBSC), US Centers for Disease Control, FDA, and EMA in roles as an invited expert and as an advisor.